Cura Health and Novo Nordisk Strengthen Commitment to Healthcare Innovation with the Launch of Wegovy ® (Semaglutide2.4mg) for People Living with Obesity in Kuwait 

Kuwait(News Desk):: Cura Health, a leading supplier of pharmaceuticals, and Novo Nordisk, the Danish leading global healthcare company renowned for its expertise in treating chronic diseases such as diabetes and obesity, announced the availability of Wegovy ® in Kuwait, at a press conference held on October 1, 2025.

The event was attended by H.E. the Danish Ambassador to Kuwait, Saudi Arabia, Bahrain, Oman,and Yemen Mrs. Liselotte Plesner, Mr. Faisal Al Mutawa Chairman & Chief Executive Officer of Cura Health, and Novo Nordisk’s General Manager for Gulf Emerging Markets Mr. Venkat Kalyan, in the presence of Dr. Waleed AlDahi, Chairman & President of Kuwait Diabetes Society, as well as Dr. Asrar Alsayed Hashem, President of Kuwait Obesity Association, along with distinguished guests and media representatives.
Obesity has emerged as a significant global epidemic, affecting approximately 1 billion individuals world-wide. Obesity in the Gulf is rapidly unfolding with the highest rates globally Adults in Kuwait living with obesity represent 44% of the population – one of the highest obesity rates globally, and 80% of the population are overweight  . The availability of products such as Wegovy ®represent a critical step in tackling a national health issue, addressing obesity and its associated complications. With six out of ten adults in the country affected by weight-related conditions, clinically proven treatment options are expected to play a significant role in easing the burden on healthcare
systems and enhancing the quality of life for Kuwaiti people.

Wegovy ® is indicated to be used in addition to reduced calorie intake and increased physical activity for weight management, including weight loss and weight maintenance in adults with obesity (BMI ≥ 30 kg/m 2 ) or with overweight (BMI ≥ 27 kg/m 2 ) in the presence of at least one weight-related comorbidity.
Wegovy ® (Semaglutide 2.4mg), the first and only once-weekly GLP-1 receptor agonist (GLP-1RA), is indicated for chronic weight management in adults and adolescents aged 12 years and above 3,4 . The active ingredient in Wegovy ® , Semaglutide 2.4 mg, works by reducing hunger and increasing the feeling of fullness. As per clinical research, Wegovy ® on top of diet and exercise delivers 17% mean
weight loss sustained over 2 years with one third of patients having a reduction of at least 20% body weight loss 3,5,6,7 . Semaglutide 2.4 mg demonstrated significant improvements in other cardiometabolic risk factors such as: waist circumference, blood pressure, lipid profile, glycemic parameters & C- reactive protein 3,8,9 .

The SELECT clinical study including 17,604 adults with a BMI ≥27 kg/m2 demonstrated that Wegovy ®(Semaglutide 2.4mg) resulted in a statistically significant 20% risk reduction in cardiovascular death, heart attacks and stroke in adults with overweight or obesity and established cardiovascular disease, without T2DM 1,9 .
Mr. Faisal Al Mutawa: The Chairman and CEO of Cura Health stated:
“Our collaboration with Novo Nordisk on the launch of Wegovy ® in Kuwait represents a shared commitment to advancing healthcare innovation and improving patient outcomes. At Cura Health, we believe that access to world-class treatments is essential to building a healthier future for our community, and partnerships like this are key to making that vision a reality.”
“The introduction of Wegovy ® marks a milestone in addressing obesity and its complications in Kuwait, with a focus on combatting non-communicable diseases through advanced treatments,” announced Mr. Venkat Kalyan the General Manager, Gulf Emerging Markets in Novo Nordisk. “At Novo Nordisk, we bring decades of global expertise in obesity and diabetes care to support the well-being
of the people in Kuwait. Our commitment to advancing health outcomes includes providing access to innovative therapies that encourage sustainable weight management, aligned with our broader mission to improve quality of life.”
Dr. Waleed Al-Dahi, President of Kuwait Diabetes Society emphasized:
Obesity is a serious and chronic disease, and a leading contributor to multiple comorbidities such as type 2 diabetes and cardiovascular conditions. “He noted that “Kuwait ranks among the highest globally in obesity prevalence, which underscores the urgent need for collaborative efforts across all sectors to address this growing public health challenge. “Dr. Al-Dahi also highlighted the importance
of GLP-1 therapies like Wegovy ®️ , which play a vital role in improving health outcomes and saving lives by offering patients an effective tool to manage obesity.
Dr. Asrar Alsayed Hashem, President of Kuwait Obesity Association stated:
“The launch of Wegovy ® in Kuwait represents a significant addition to the range of available treatments for combating obesity. As our scientific understanding of obesity continues to evolve—as a chronic, multifactorial disease—it becomes increasingly important to offer a variety of personalized treatment options that address each patient’s unique needs. These range from lifestyle modifications
and pharmacological therapies to surgical interventions when necessary.” she added:
“Wegovy ® is an effective medication that reduces appetite, regulates blood sugar levels, and promotes weight loss. It has demonstrated strong efficacy and safety in achieving meaningful weight reduction among both adults and adolescents (from age 12), along with improvements in risk factors associated with chronic diseases.”
H.E. the Danish Ambassador to Kuwait, Saudi Arabia, Bahrain, Oman, and Yemen, Mrs.
Liselotte Plesner highlighted the strategic collaboration between Novo Nordisk and the Kuwaiti Ministry of Health: “Denmark is proud to see one of its leading companies working hand-in-hand with Kuwait’s Ministry of Health to address the growing burden of obesity and chronic diseases. Together, we are not only advancing medical innovation but also reaffirming our shared commitment to
improving lives through sustainable healthcare solutions.”